Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Alexander P. J. Vlaar(University of Amsterdam), Diederik van de Beek(University of Amsterdam), Janneke Horn(Amsterdam University Medical Centers), Frederique Paulus(Amsterdam University Medical Centers), Marcus J. Schultz(University of St.Gallen), E. Marleen Kemper(Amsterdam University Medical Centers), Iwan C.C. van der Horst(Maastricht University Medical Centre), W. Joost Wiersinga(Amsterdam Neuroscience), Liora ter Horst(Amsterdam Neuroscience), Matthias H. Busch(Maastricht University Medical Centre), Ingeborg E. van Zeggeren(Amsterdam Neuroscience), Simon Rueckinger, Korinna Pilz(Inflarx (Germany)), Martin Witzenrath(Humboldt-Universität zu Berlin), Lieuwe D. J. Bos(Amsterdam Neuroscience), Leo Heunks(Radboud University Nijmegen), Sjoerd A.M.E.G. Timmermans(Maastricht University Medical Centre), Esther Bulle(Amsterdam University Medical Centers), Rutger Koning(Amsterdam University Medical Centers), Marcel C.G. van de Poll(Maastricht University Medical Centre), Niels C. Riedemann(Inflarx (Germany)), Sanne de Bruin(Amsterdam University Medical Centers), Frank E.H.P. van Baarle(Amsterdam University Medical Centers), Pieter van Paassen(Maastricht University Medical Centre), Ren-Feng Guo(University of Michigan), Matthijs C. Brouwer(University of Amsterdam)
Cited by 199
Related Papers
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.2k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
|Critical Care Medicine|2021|2.8k
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k